Drug combination for treating or preventing fatty hyperlipidemia

A composition and a technology for hyperlipidemia, applied in the field of medicine, can solve problems such as the growth of degradation products, and achieve the effects of small dosage, low toxicity and less side reactions

Inactive Publication Date: 2016-01-13
QINGDAO YUNTIAN BIOTECH
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This invention does not fundamentally solve the stability problem of rosuvastatin calcium. Since all the excipients have relatively high hygroscopicity, the degradation products will still increase significantly during storage.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug combination for treating or preventing fatty hyperlipidemia
  • Drug combination for treating or preventing fatty hyperlipidemia
  • Drug combination for treating or preventing fatty hyperlipidemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020]

[0021]

[0022] Preparation Process:

[0023] Weigh orlistat and acipimox according to the prescription quantity, use microcrystalline cellulose as filler, croscarmellose sodium and polyvinylpyrrolidone as disintegrants, 6% PVP60% ethanol solution as binder agent, magnesium stearate as a glidant, granulated in one step with a fluidized bed, and then compressed into tablets, to obtain.

Embodiment 2

[0025]

[0026] Preparation Process:

[0027] Weigh orlistat and acipimox according to the prescription quantity, use microcrystalline cellulose as filler, croscarmellose sodium and polyvinylpyrrolidone as disintegrants, 6% PVP60% ethanol solution as binder Sodium stearate fumarate is used as a glidant, granulated in one step in a fluidized bed, and then compressed into tablets.

Embodiment 3

[0029]

[0030] Preparation Process:

[0031] Weigh orlistat and acipimox according to the prescription quantity, use microcrystalline cellulose and precrossified starch as fillers, croscarmellose sodium and polyvinylpyrrolidone as disintegrants, 5% PVP60% The ethanol solution is used as a binder, the micropowdered silica gel is used as a flow aid, and it is granulated by a fluidized bed in one step, and then compressed into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a drug combination for treating or preventing fatty hyperlipidemia, in particular to a drug combination containing orlistat or cetilistat and acipimox, and belongs to the field of pharmaceuticals. The drug combination can be solid preparations such as conventional tablets, dispersible tablets, sustained-release tablets, capsules and granules. Experiments accidentally show that a drug combination containing orlistat or cetilistat and rosuvastatin calcium has an obvious synergistic effect in the aspects of lowering serum total cholesterol, serum triglyceride and low-density lipoprotein cholesterol. A preparation method is simple, convenient to operate and suitable for industrialized production.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating or preventing obese hyperlipidemia, which belongs to the field of medicine. Background technique [0002] Obesity—a problem that cannot be ignored in real life, entangles the entire human being like a "disease". Obesity spreads like a plague in developed countries and developing countries with rapid economic development, and the incidence rate is increasing year by year. Due to people's life With the improvement of the level of obesity and the change of dietary structure, obesity appears younger. For the treatment of this disease, for the treatment of obesity, the popular weight-loss western medicines in the market are divided into two categories: central nervous system acting drugs and non-central nervous acting drugs. In my country, fenfluramine and sibutramine are the most common of the former, among which fenfluramine was banned in the United States as early as 1997 because it may ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4965A61K31/536A61P3/06A61K31/365
Inventor 王传秀
Owner QINGDAO YUNTIAN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap